MedTrace Logo

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

NCT03362190 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-06-10

Study results available
· View outcomes & findings →

Summary

To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Avacincaptad Pegol

Avacincaptad Pegol in combination with Lucentis

DRUG

Lucentis

Avacincaptad Pegol in combination with Lucentis

Sponsors & Collaborators

  • Ophthotech Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-11
Primary Completion
2018-10-18
Completion
2018-10-18
FDA Drug
Yes

Countries

  • United States
  • Hungary
  • Latvia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362190 on ClinicalTrials.gov